Estimating medication persistency using administrative claims data.

OBJECTIVES To review the definitions and methods for measuring medication persistency, and to propose a uniform definition of and calculation for persistency using pharmacy claims data. STUDY DESIGN Literature review. METHODS A MEDLINE search (1966 to present) was performed to identify articles detailing a definition or method of persistency measurement based on automated pharmacy data. Articles were screened for relevance by title and abstract. References from identified articles were used to expand the search results. RESULTS The concept behind medication persistency measurement is to capture the amount of time that an individual remains on chronic drug therapy. The methods to calculate medication persistency can be classified into 1 of 3 categories: (1) Persistency as a function of the medication possession ratio; (2) persistency as a function of medication availability at a fixed point in time; and (3) persistency as a function of the gaps between refills. CONCLUSIONS The common goal of all persistency measures should be to reflect the continuity of medication usage and to capture the timeliness and the frequency of refilling. The measurement of persistency as a function of the gaps between refills provides the best assessment of refill compliance across a variety of medication and disease states and lends itself to the well-established measurements of survival analysis.

[1]  D. Sclar,et al.  Utility of a transdermal delivery system for antihypertensive therapy. Part 2. , 1991, The American journal of medicine.

[2]  C. Dezii A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. , 2000, Managed care.

[3]  M. Gill,et al.  Antiretroviral medication adherence and persistence with respect to adherence tool usage. , 2000, AIDS patient care and STDs.

[4]  Hu Js,et al.  Relationship of compliance with hormone replacement therapy to short-term healthcare utilization in a managed care population. , 1998 .

[5]  J. LeLorier,et al.  Predictors of persistence of use of the novel antidiabetic agent acarbose. , 2001, Archives of internal medicine.

[6]  J. Caro Stepped care for hypertension: are the assumptions valid? , 1997, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[7]  J. K. Won,et al.  Effect of value–added utilities on prescription refill compliance and Medicaid health care expenditures–a study of patients with non–insulin–dependent diabetes mellitus , 1993, Journal of clinical pharmacy and therapeutics.

[8]  M. Weinstein,et al.  Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.

[9]  G. Schwartz,et al.  Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. , 2004, American journal of ophthalmology.

[10]  M. Tran,et al.  Effects of Once-Daily and Twice-Daily Dosing on Adherence With Prescribed Glipizide Oral Therapy for Type 2 Diabetes , 2002, Southern medical journal.

[11]  L. Pilote,et al.  The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[12]  C. Mullins,et al.  Discontinuation rates of topical glaucoma medications in a managed care population. , 2002, The American journal of managed care.

[13]  G. Schwartz,et al.  Patient persistency with topical ocular hypotensive therapy in a managed care population. , 2004, American journal of ophthalmology.

[14]  Urs A. Meyer,et al.  Drug regimen compliance : issues in clinical trials and patient management , 1999 .

[15]  B. Martin,et al.  Persistence with Estrogen Therapy in a Postmenopausal Medicaid Population , 1999, Pharmacotherapy.

[16]  W. Gerth Compliance and persistence with newer antihypertensive agents , 2002, Current hypertension reports.

[17]  D. Sclar,et al.  Antidepressant Pharmacotherapy: Economic Evaluation of Fluoxetine, Paroxetine and Sertraline in a Health Maintenance Organization , 1995, The Journal of international medical research.

[18]  Hugh Kawabata,et al.  Young HIV-infected adults are at greater risk for medication nonadherence. , 2002, MedGenMed : Medscape general medicine.

[19]  F. Stracci,et al.  Statin compliance in the Umbrian population , 2003, European Journal of Clinical Pharmacology.

[20]  S. Benson,et al.  Immediate‐Release Oxybutynin versus Tolterodine in Detrusor Overactivity: A Population Analysis , 2000, Pharmacotherapy.

[21]  J. Kennedy,et al.  Drug affordability and prescription noncompliance in the United States: 1997-2002. , 2004, Clinical therapeutics.

[22]  P A Russo,et al.  The economic burden of congestive heart failure in a managed care population. , 2000, The American journal of managed care.

[23]  G. Dailey,et al.  Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. , 2001, Clinical therapeutics.

[24]  J. LeLorier,et al.  Estrogen Replacement Therapy: Determinants of Persistence With Treatment , 2001, Obstetrics and gynecology.

[25]  A V Prochazka,et al.  The assessment of refill compliance using pharmacy records: methods, validity, and applications. , 1997, Journal of clinical epidemiology.

[26]  S. Crystal,et al.  Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS , 2001, Journal of General Internal Medicine.

[27]  J. Métry Measuring Compliance in Clinical Trials and Ambulatory Care , 2002 .

[28]  F. Frech,et al.  Patient Adherence With Amlodipine, Lisinopril, or Valsartan Therapy in a Usual-Care Setting , 2003, Journal of managed care pharmacy : JMCP.

[29]  J. Rizzo,et al.  Variations in compliance among hypertensive patients by drug class: implications for health care costs. , 1997, Clinical therapeutics.

[30]  Y. Moride,et al.  Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. , 2003, Rheumatology.

[31]  G. Dailey,et al.  Patient Compliance and Persistence with Anti-Hyperglycemic Therapy: Evaluation of a Population of Type 2 Diabetic Patients , 2002, The Journal of international medical research.

[32]  J. Avorn,et al.  Persistence of use of lipid-lowering medications: a cross-national study. , 1998, JAMA.

[33]  D. Cm Persistence with drug therapy: a practical approach using administrative claims data. , 2001 .

[34]  W. Drevets,et al.  Course of antidepressant treatment drug type, and prescriber's specialty. , 1998, Psychiatric services.

[35]  A. Perwien,et al.  Stimulant Treatment Patterns and Compliance in Children and Adults With Newly Treated Attention-Deficit/Hyperactivity Disorder , 2004, Journal of managed care pharmacy : JMCP.

[36]  R. Aubert,et al.  Evaluation of a depression health management program to improve outcomes in first or recurrent episode depression. , 2003, The American journal of managed care.

[37]  J. K. Won,et al.  Utility of a sustained-release formulation for antihypertensive therapy. , 1993, Journal of human hypertension.

[38]  L. Pilote,et al.  Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. , 2003, American heart journal.

[39]  J Urquhart,et al.  Some economic consequences of noncompliance , 2001, Current hypertension reports.

[40]  J. K. Won,et al.  Effect of value-added utilities on prescription refill compliance and health care expenditures for hypertension. , 1993, Journal of human hypertension.

[41]  J. LeLorier,et al.  Patterns of amlodipine and felodipine use in an elderly Quebec population. , 2000, The Canadian journal of cardiology.

[42]  G. Baio,et al.  A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. , 2002, Clinical therapeutics.

[43]  M. Rich,et al.  Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. , 1999, American heart journal.

[44]  G. Schwartz,et al.  Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. , 2003, Clinical therapeutics.

[45]  A. Capone,et al.  Pharmacoeconomics of Antihypertensive Drug Treatment: An Analysis of How Long Patients Remain on Various Antihypertensive Therapies , 2004, Journal of clinical hypertension.

[46]  J. Caro,et al.  Existing treatment strategies: does noncompliance make a difference? , 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[47]  W. Gerth,et al.  Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. , 2001, Clinical therapeutics.

[48]  G. Schwartz,et al.  Patient Persistency with Pharmacotherapy in the Management of Glaucoma , 2003, European journal of ophthalmology.

[49]  J. Hasford,et al.  A population-based European cohort study of persistence in newly diagnosed hypertensive patients , 2002, Journal of Human Hypertension.

[50]  G. Schwartz,et al.  Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. , 2002, The American journal of managed care.

[51]  B. Bloom Continuation of initial antihypertensive medication after 1 year of therapy. , 1998, Clinical therapeutics.

[52]  Eric S. Johnson,et al.  Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. , 2002, The American journal of managed care.

[53]  J. P. Wilson,et al.  Patterns of antihypertensive use among patients in the US Department of Defense database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker. , 1997, Clinical therapeutics.

[54]  D. Sclar,et al.  Effect of health education in promoting prescription refill compliance among patients with hypertension. , 1991, Clinical therapeutics.

[55]  J. Kragstrup,et al.  High persistence of statin use in a Danish population: compliance study 1993-1998. , 2002, British journal of clinical pharmacology.

[56]  S. Crystal,et al.  The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. , 1995, Health services research.

[57]  S. Piñeros,et al.  Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. , 2003, The American journal of cardiology.

[58]  J. Caro,et al.  Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[59]  R. Düsing,et al.  Adverse events, compliance, and changes in therapy , 2001, Current hypertension reports.

[60]  J. Caro,et al.  Persistence with treatment for hypertension in actual practice. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[61]  W. Gerth,et al.  Antihypertensive persistence and drug class. , 2002, The Canadian journal of cardiology.

[62]  Anke Richter,et al.  The impact of reducing dose frequency on health outcomes. , 2003, Clinical therapeutics.